Formycon AG (FSB: FYB, Prime Standard) announced today that it will release its financial results for the fiscal year 2025 on April 22, 2026. The Management Board will host a conference call and webcast at 3:00 PM CEST to discuss the company's development, key financial figures, and provide an outlook for 2026. Registration for the call is available at https://webcast.meetyoo.de/reg/lNibT8TVWubG, and the presentation and audio broadcast can be accessed via https://www.webcast-eqs.com/formycon-2025-fy. A recording will be posted on the Formycon website at https://www.formycon.com/en/investor-relations/publications/.
The announcement comes as Formycon continues to strengthen its position as a leading independent developer of biosimilars, with two products already on the market—FYB201/ranibizumab and FYB202/ustekinumab—and FYB203/aflibercept approved by the FDA, EMA, and MHRA. The company's pipeline includes four candidates, such as FYB208/dupilumab, targeting therapies in ophthalmology, immunology, and immuno-oncology. With global biosimilar sales projected to rise from $21 billion to over $74 billion by 2030, Formycon's progress is significant for investors and healthcare systems seeking cost-effective biologic alternatives.
In the second quarter of 2026, Formycon management will attend several investor conferences, underscoring the company's commitment to engaging with the financial community. Events include the Equity Forum Spring Conference in Frankfurt (May 11-12), the Jefferies Global Healthcare Conference in New York City (June 2-4), the mwb research Roundtable (June 8), and the UBS Life Sciences Conference in London (June 18). Additionally, the annual general meeting will be held on June 10 in Munich. Details are available on the company's financial calendar at https://www.formycon.com/en/investors/financial-calendar/.
Formycon's focus on biosimilars addresses a critical need: as biopharmaceutical patents expire on blockbuster drugs with over $200 billion in annual sales by 2032, biosimilars offer affordable access to life-saving therapies. The company's upcoming financial results and conference participation will provide insights into its operational performance and strategic direction amid this growing market.
